Comparative Pharmacology
Head-to-head clinical analysis: PHERAZINE W CODEINE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHERAZINE W CODEINE versus QDOLO.
PHERAZINE W/ CODEINE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative. It also exerts anticholinergic and antidopaminergic effects, particularly at D2 receptors. Codeine is an opioid agonist primarily at mu-opioid receptors, leading to analgesia and antitussive effects. The combination enhances sedation and antiemetic action.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
One tablet (promethazine 6.25 mg / codeine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets in 24 hours.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Promethazine: 9-16 hours in adults; codeine: 2.5-3.5 hours; morphine: 1.5-2 hours. Clinical context: The half-life of codeine is shorter, but its active metabolite morphine contributes to analgesia. Accumulation may occur with repeated dosing.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal (50-70% as unchanged promethazine and metabolites; codeine and its metabolites, primarily morphine and codeine-6-glucuronide, are excreted renally). Biliary/fecal elimination accounts for less than 10%.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist